Based on the Atara Biotherapeutics Inc stock forecast from 2 analysts, the average analyst target price for Atara Biotherapeutics Inc is USD 17.40 over the next 12 months. Atara Biotherapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Atara Biotherapeutics Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Atara Biotherapeutics Inc’s stock price was USD 5.89. Atara Biotherapeutics Inc’s stock price has changed by -3.92% over the past week, -14.64% over the past month and -68.56% over the last year.
No recent analyst target price found for Atara Biotherapeutics Inc
No recent average analyst rating found for Atara Biotherapeutics Inc
Company Overview Atara Biotherapeutics Inc
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California. Read Less
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 cli...Read More
Frequently Asked Questions About Atara Biotherapeutics Inc (ATRA) Stock
Based on ratings from 2 analysts Atara Biotherapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ATRA's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for ATRA is USD 17.40 over the next 12 months. The maximum analyst target price is USD 25 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on ATRA's stock to indicate if its overvalued.
The last closing price of ATRA's stock was USD 5.89.
The most recent market capitalization for ATRA is USD 0.04B.
Based on targets from 2 analysts, the average taret price for ATRA is projected at USD 17.40 over the next 12 months.
This means that ATRA's stock price may go up by +195.42% over the next 12 months.
We can't find any ETFs which contains Atara Biotherapeutics Inc's stock.
As per our most recent records Atara Biotherapeutics Inc has 153 Employees.
Atara Biotherapeutics Inc's registered address is 1280 Rancho Conejo Blvd, Thousand Oaks, CA, United States, 91320.
You can get more information about it from Atara Biotherapeutics Inc's website at https://www.atarabio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Atara Biotherapeutics Inc (ATRA) Stock
Based on ratings from 2 analysts Atara Biotherapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 4 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on ATRA's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for ATRA is USD 17.40 over the next 12 months. The maximum analyst target price is USD 25 while the minimum anlayst target price is USD 7.
Unfortunately we do not have enough data on ATRA's stock to indicate if its overvalued.
The last closing price of ATRA's stock was USD 5.89.
The most recent market capitalization for ATRA is USD 0.04B.
Based on targets from 2 analysts, the average taret price for ATRA is projected at USD 17.40 over the next 12 months.
This means that ATRA's stock price may go up by +195.42% over the next 12 months.
We can't find any ETFs which contains Atara Biotherapeutics Inc's stock.
As per our most recent records Atara Biotherapeutics Inc has 153 Employees.
Atara Biotherapeutics Inc's registered address is 1280 Rancho Conejo Blvd, Thousand Oaks, CA, United States, 91320.
You can get more information about it from Atara Biotherapeutics Inc's website at https://www.atarabio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ATRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
